Qing Xia

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Topics

Multiple Myeloma

Chronic Kidney Disease

Top Venues

Leukemia & lymphoma

Pharmaceutical statistics

This page only lists publications with an associated author ORCID identifier.

Publications

Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma (2024)
Qing Xia, Kentaro Takeda, Yusuke Yamaguchi, Jun Zhang
A generalized Bayesian optimal interval design for dose optimization in immunotherapy. Pharmaceutical statistics (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma 65 (6) (2024)
Qing Xia, Kentaro Takeda, Yusuke Yamaguchi, Jun Zhang
A generalized Bayesian optimal interval design for dose optimization in immunotherapy. Pharmaceutical statistics 23 (4) (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma 65 (6) (2024)
Aurore Perrot, Sosana Delimpasi, Emmanouil Spanoudakis, Ulf Frølund, Angelo Belotti, Albert Ortiol, Phillipe Moreau, Ian McFadden, Qing Xia, Mukta Arora, Meletios- Athanasios Dimopoulos
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leukemia & lymphoma 65 (6) (2024)